Privia Health Group, Inc. $PRVA Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH increased its position in Privia Health Group, Inc. (NASDAQ:PRVA) by 165.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 39,243 shares of the company’s stock after acquiring an additional 24,433 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Privia Health Group were worth $933,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Canada Pension Plan Investment Board grew its holdings in shares of Privia Health Group by 48.0% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock worth $85,000 after acquiring an additional 1,200 shares during the period. GAMMA Investing LLC grew its holdings in Privia Health Group by 198.5% during the 4th quarter. GAMMA Investing LLC now owns 4,314 shares of the company’s stock valued at $102,000 after buying an additional 2,869 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Privia Health Group during the 2nd quarter valued at $113,000. Covestor Ltd grew its holdings in Privia Health Group by 39.8% during the 3rd quarter. Covestor Ltd now owns 5,824 shares of the company’s stock valued at $145,000 after buying an additional 1,657 shares during the last quarter. Finally, CWM LLC grew its holdings in Privia Health Group by 94.2% during the 3rd quarter. CWM LLC now owns 6,634 shares of the company’s stock valued at $165,000 after buying an additional 3,218 shares during the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

Insider Transactions at Privia Health Group

In other news, CFO David Mountcastle sold 5,566 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $20.85, for a total transaction of $116,051.10. Following the sale, the chief financial officer owned 214,847 shares in the company, valued at $4,479,559.95. This trade represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Edward C. Fargis sold 4,949 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $22.84, for a total value of $113,035.16. Following the sale, the executive vice president owned 83,711 shares in the company, valued at $1,911,959.24. This trade represents a 5.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 247,757 shares of company stock worth $5,636,639 over the last quarter. 5.70% of the stock is currently owned by insiders.

Privia Health Group Price Performance

NASDAQ:PRVA opened at $24.85 on Monday. The firm has a 50 day simple moving average of $22.59 and a 200-day simple moving average of $23.37. The firm has a market cap of $3.12 billion, a PE ratio of 146.18, a P/E/G ratio of 1.55 and a beta of 0.96. Privia Health Group, Inc. has a 1-year low of $18.77 and a 1-year high of $26.51.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The business had revenue of $541.17 million for the quarter, compared to analysts’ expectations of $516.61 million. During the same quarter last year, the firm earned $0.21 earnings per share. The business’s revenue was up 17.4% on a year-over-year basis. As a group, sell-side analysts expect that Privia Health Group, Inc. will post 0.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Piper Sandler reiterated an “overweight” rating and set a $36.00 target price on shares of Privia Health Group in a report on Thursday, February 26th. Truist Financial increased their target price on Privia Health Group from $31.00 to $33.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Canaccord Genuity Group increased their target price on Privia Health Group from $34.00 to $35.00 and gave the company a “buy” rating in a report on Friday, February 27th. Barclays increased their target price on Privia Health Group from $23.00 to $25.00 and gave the company an “equal weight” rating in a report on Wednesday, March 25th. Finally, Citigroup lowered their target price on Privia Health Group from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Eleven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Privia Health Group currently has an average rating of “Moderate Buy” and an average price target of $31.31.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.